Key facts
- This page summarizes Carl L. Gordon's Form 4 filing for Terns Pharmaceuticals, Inc. (TERN).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 02 Jul 2024, 18:36.
Carl L. Gordon - 01 Jul 2024 Form 4 Insider Report for Terns Pharmaceuticals, Inc. (TERN)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- TERN
- Reported as of
- 01 Jul 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Jul 2024, 18:36:23 UTC
- Prior SEC filing
- 14 Jun 2024
- Next SEC filing
- 17 Jul 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Bryan Yoon, as Attorney-in-Fact for Carl Gordon
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Carl L. Gordon filed Form 4 for Terns Pharmaceuticals, Inc. (TERN) on 02 Jul 2024.
Change
- Previous filing in this sequence was filed on 14 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TERN
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +4,676
- Change %
- Price
- $0.000000
- Shares after
- 4,676
- Date
- 01 Jul 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,676
- Exercise price
- $6.85
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
This option was issued pursuant to the Issuer's Non-Employee Director Compensation Policy, under which the Reporting Person elected to receive this option in lieu of the Reporting Person's cash retainer fee of $20,000 for the third and fourth quarters of 2024.
Footnote F2
The option will vest as to 1/6th of the total shares subject thereto on each monthly anniversary of the date of grant, such that 100% of the shares subject to the option will be fully vested on January 1, 2025.
Footnote F3
Pursuant to an agreement with OrbiMed Advisors LLC, OrbiMed Asia GP III, L.P., OrbiMed Advisors III Limited, and OrbiMed Capital GP VII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC, OrbiMed Asia GP III, L.P., OrbiMed Advisors III Limited, and OrbiMed Capital GP VII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Asia Partners III, L.P. and OrbiMed Private Investments VII, LP.